Accelerating drug discovery: Although the evolution of '-omics' methodologies is still in its infancy, both the pharmaceutical industry and patients could benefit from their implementation in the drug development process

EMBO Reports

Volumn 5, Issue 9, 2004, Pages 837-842

  Kraljevic, Sandra ^a   Stambrook, Peter J ^b   Pavelic, Kresimir ^a  

^a RUDER BO KOVI INSTITUTE   (Croatia)

^b UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; MERCAPTOPURINE; NEW DRUG; THIOPURINE METHYLTRANSFERASE; TRASTUZUMAB; DRUG;

BREAST CANCER; CHILDHOOD LEUKEMIA; COMBINATORIAL CHEMISTRY; DNA MICROARRAY; DRUG APPROVAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG QUALITY; DRUG RESEARCH; DRUG SAFETY; DRUG TARGETING; ETHNIC DIFFERENCE; FINANCIAL MANAGEMENT; FOOD AND DRUG ADMINISTRATION; FUNCTIONAL GENOMICS; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOTYPE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN GENETICS; INDIVIDUALIZATION; MASS SPECTROMETRY; METHODOLOGY; NONHUMAN; OPEN READING FRAME; PATIENT CARE; PHARMACOGENETICS; PREDICTION; PRIORITY JOURNAL; PROTEIN PROCESSING; PROTEOMICS; QUALITY OF LIFE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TOXICITY TESTING; TOXICOGENETICS; TRANSCRIPTOMICS; TREATMENT OUTCOME; TWO DIMENSIONAL GEL ELECTROPHORESIS; UNITED STATES; X RAY CRYSTALLOGRAPHY; ANIMAL; ARTICLE; GENOMICS; TIME;

ANIMALS; DRUG APPROVAL; GENOMICS; HUMANS; PHARMACEUTICAL PREPARATIONS; TIME FACTORS;

EID: 16644402982     PISSN: 1469221X     EISSN: 14693178     Source Type: Journal    
DOI: 10.1038/sj.embor.7400236     Document Type: Review

References (31)

1. Aardema MJ, MacGregor JT (2002) Toxicology and genetic toxicology in the new era of "toxicogenomics": Impact of "-omics" technologies. Mutat Res 499: 13-25
2. Amin RP et al (2004) Identification of putative ene-based markers of renal toxicity. Environ Health Perspect 112: 465-479
3. Ball CA et al; Microarray Gene Expression Data (MGED) Society (2002) Standards for microarray data. Science 298: 539
4. Banks RE, Dunn MJ, Hochstrasser DF, Sanchez JC, Blackstock W, Pappin DJ, Selby PJ (2000) Proteomics: New perspectives, new biomedical opportunities. Lancet 356: 1749-1756
5. Boorman GA, Anderson SP, Casey WM, Brown RH, Crosby LM, Gottschalk K, Easton M, Ni H, Morgan KT (2002) Toxicogenomics, drug discovery and the pathologist. Toxicol Pathol 30: 15-27
6. Brazma A et al (2001) Minimum information about a microarray experiment (MIAME) - toward standards for microarray data. Nat Genet 29: 365-371
7. Burczynski ME, McMillian M, Ciervo J, Li L, Parker JB, Dunn RT 2nd, Hicken S, Farr S, Johnson MD (2000) Toxicogenomics-based discrimination of toxic mechanism in HepG2 human hepatoma cells. Toxicol Sci 58: 399-415
8. Castle AL, Carver MP, Mendrick DL (2002) Toxicogenomics: A new revolution in drug safety. Drug Discov Today 7: 728-736
9. Choudhary J, Grant SG (2004) Proteomics in postgenomic neuroscience: The end of the beginning. Nat Neurosci 7: 440-445
10. Dolle RE (2002) Comprehensive survey of combinatorial library synthesis: 2001. J Comb Chem 4: 369-418
11. Eisenberg RS (2002) Will pharmacogenomics alter the role of patents in drug development? Pharmacogenomics 3: 571-574
12. Evans WE, Johnson JA (2001) Pharmacogenomics the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2: 9-39
13. Fountoulakis M, Suter L (2002) Proteomic analysis of the rat liver. J Chromatogr B Analyt Technol Biomed Life Sci 782: 197-218
14. Gershon D (2002) Microarray technology: An array of opportunities. Nature 416: 885-891
15. Goldstein DB (2003) Pharmacogenetics in the laboratory and the clinic. New Engl. J Med 348: 553-556
16. Hamadeh HK et al (2002) Gene expression analysis reveals chemical-specific profiles. Toxicol Sci 67: 219-231
17. Jorgensen WL (2004) The many roles of computation in drug discovery. Science 303: 1813-1818
18. Jungblut PR, Muller EC, Mattow J, Kaufmann SH (2001) Proteomics reveals open reading frames in Mycobacterium tuberculosis H37Rv not predicted by gemomics. Infect Immun 69: 5905-5907
19. Kramer JA, Kolaja KL (2002) Toxicogenomics: An opportunity to optimise drug development and safety evaluation. Expert Opin Drug Saf 1 275-286
20. Lazarou J, Pomeranz BH, Corey PN (1998) Incidence of adverse drug reactions in hospitalized patients. JAMA 279: 1200-1205
21. Lefkovits I (2003) Functional and structural proteomics: A critical appraisal. J Chromatogr B Analyt Technol Biomed Life Sci 787 1-10
22. Lesko LJ, Atkinson AJ (2001) Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: Criteria, validation, strategies. Annu Rev Pharmacol Toxicol 41: 347-366
23. Lindon JC, Holmes E, Nicholson JK (2004) Metabonomics and its role in drug development and disease diagnosis. Expert Rev Mol Diagn 4 189-199
24. LoPachin RM, Jones RC, Patterson TA, Slikker W, Barber DS (2003) Application of proteomics to the study of molecular mechanisms in neurotoxicology. Neurotoxicology 24: 761-775.
25. Macgregor PF (2003) Gene expression in cancer: The application of microarrays. Expert Rev Mol Diagn 3: 186-200
26. Michelson S, Joho K (2000) Drug discovery, drug development and the emerging world of pharmacogenomics: Prospecting for information in a data-rich landscape. Curr Opin Mol Ther 2: 651-654
27. Newton RK, Aardema M, Aubrecht J (2004) The utility of DNA microarrays for characterizing genotoxicity. Environ Health Perspect 112 420-422
28. Novak JP, Sladek R, Hudson TJ (2002) Characterization of variability in large-scale gene expression data: Implications for study design. Genomics 79: 104-113
29. Robosky LC, Robeftm DG, Baker JD, Rane S, Reily MD (2002) In vivo toxicity screening programs using metabonomics. Comb Chem High Throughput Screen 5: 651-662
30. Snodin DJ (2002) An EU perspective on the use of in vitro methods in regulatory pharmaceutical toxicology. Toxicol Lett 127: 161-168
31. Waring JF, Jolly RA, Ciurlionis R, Lum PY, Praestgaard JT, Morfitt DC, Buratto B, Roberts C, Schadt E, Ulrich RG (2001) Clustering of hepatotoxins based on mechanism of toxicity using gene-expression profiles. Toxicol Appl Pharmacol 175: 28-42